DK2782566T3 - L-serin til anvendelse ved behandling af neurodegenerative lidelser - Google Patents

L-serin til anvendelse ved behandling af neurodegenerative lidelser Download PDF

Info

Publication number
DK2782566T3
DK2782566T3 DK12851576.4T DK12851576T DK2782566T3 DK 2782566 T3 DK2782566 T3 DK 2782566T3 DK 12851576 T DK12851576 T DK 12851576T DK 2782566 T3 DK2782566 T3 DK 2782566T3
Authority
DK
Denmark
Prior art keywords
serin
treatment
neurodegenerative disorders
neurodegenerative
disorders
Prior art date
Application number
DK12851576.4T
Other languages
English (en)
Inventor
Kenneth Rodgers
Rachael Dunlop
Paul A Cox
Original Assignee
The Inst For Ethnomedicine
Kenneth Rodgers
Rachael Dunlop
Paul A Cox
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Inst For Ethnomedicine, Kenneth Rodgers, Rachael Dunlop, Paul A Cox filed Critical The Inst For Ethnomedicine
Application granted granted Critical
Publication of DK2782566T3 publication Critical patent/DK2782566T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Environmental Sciences (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK12851576.4T 2011-11-21 2012-11-21 L-serin til anvendelse ved behandling af neurodegenerative lidelser DK2782566T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161562194P 2011-11-21 2011-11-21
PCT/US2012/066373 WO2013078395A1 (en) 2011-11-21 2012-11-21 L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders

Publications (1)

Publication Number Publication Date
DK2782566T3 true DK2782566T3 (da) 2021-02-08

Family

ID=48470319

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12851576.4T DK2782566T3 (da) 2011-11-21 2012-11-21 L-serin til anvendelse ved behandling af neurodegenerative lidelser

Country Status (10)

Country Link
US (5) US20130156846A1 (da)
EP (1) EP2782566B1 (da)
JP (1) JP6265908B2 (da)
AU (1) AU2012340563B2 (da)
CA (1) CA2855854C (da)
DK (1) DK2782566T3 (da)
ES (1) ES2856063T3 (da)
IL (1) IL232710B (da)
PT (1) PT2782566T (da)
WO (1) WO2013078395A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170326088A1 (en) * 2014-11-24 2017-11-16 Entrinsic Health Solutions, Llc Amino acid compositions for the treatment of symptoms of disease
US10960076B2 (en) 2017-01-25 2021-03-30 Church & Dwight Co. Inc. Gummy dosage forms comprising serine
KR20180101242A (ko) 2017-03-02 2018-09-12 주식회사 아스트로젠 엘­세린을 유효성분으로 포함하는 혈뇌장벽 장애의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품
CA3102973A1 (en) * 2018-06-08 2019-12-12 The Institute For Ethnomedicine Method of enhancing glucose levels in the central nervous system
KR101952443B1 (ko) * 2018-08-23 2019-02-26 주식회사 아스트로젠 신규한 마그네슘­세리네이트 화합물 및 이의 용도
KR102022118B1 (ko) * 2019-01-07 2019-09-18 주식회사 아스트로젠 중추신경계 질환의 예방 또는 치료용 세린 유도체 화합물
AU2020334128A1 (en) * 2019-08-21 2022-03-10 Brain Chemistry Labs Compositions comprising a metal and L-serine, and uses thereof
US20220252620A1 (en) * 2021-02-05 2022-08-11 The Institute for Ethnomedicine dba Brain Chemistry Labs Blood indicators of alzheimer's disease
CN112972458B (zh) * 2021-03-05 2022-10-04 北京北科华夏生物医药科技有限公司 一种组合物在制备阿尔兹海默症治疗药物中的应用
KR102522508B1 (ko) * 2022-12-16 2023-04-18 주식회사 아스트로젠 마그네슘-세리네이트의 신규한 결정형 및 이의 제조방법

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3873722A (en) 1974-05-31 1975-03-25 Nelson Res & Dev Method for treating schizophrenia
US4000318A (en) * 1974-08-19 1976-12-28 Commonwealth Scientific And Industrial Research Organization Amino acid supplements
US4491589A (en) * 1982-05-17 1985-01-01 The Trustees Of Columbia University In The City Of New York Amino acid solutions for parenteral nutrition and methods of formulation and use
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
SE8701662L (sv) * 1987-04-22 1988-10-23 Gelder Nico M Van Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna
JPS6440453A (en) 1987-08-05 1989-02-10 Mitsui Toatsu Chemicals Racemization of optically active serine
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
SE502280C2 (sv) 1991-12-20 1995-09-25 Bio Swede Ab Separering av aminosyror, aminosyrabaserad monomer och förfarande för framställning därav samt polymert material och förfarande för framställning därav
AU4019395A (en) 1994-11-23 1996-06-17 G.D. Searle & Co. Use of amino-isoxazolidone compounds for improvement of implicit memory
AU735687B2 (en) 1997-07-28 2001-07-12 Riken Agent for protecting central nerve cells and enhancing survival thereof
IL139008A0 (en) 1998-04-14 2001-11-25 Gen Hospital Corp Methods for treating neuropsychiatric disorders
US6984484B1 (en) * 1999-01-19 2006-01-10 The Johns Hopkins University Mammalian serine racemase
JP2002316929A (ja) * 2001-04-18 2002-10-31 Japan Science & Technology Corp L−セリン又はグリシンからなる抗アポトーシス剤
EP1536781B1 (en) * 2002-06-19 2010-02-17 N.V. Nutricia Nutritional or pharmaceutical compositions for increasing the creatine response of organisms
JP2004182705A (ja) * 2002-10-11 2004-07-02 Yasutoshi Koga ミトコンドリア機能異常に起因する疾患における臨床症状発現の予防・治療用組成物
US20050028720A1 (en) * 2003-08-05 2005-02-10 Bell Adam Warwick Pop-up device for deterring an attacking animal such as a bear
US7256002B2 (en) * 2003-08-12 2007-08-14 The Institute For Ethnomedicine Screening for neurotoxic amino acid associated with neurological disorders
US7148192B2 (en) 2004-01-29 2006-12-12 Ebwe Pharma Ges. M.H. Nfg.Kg Neuroprotective dietary supplement
FI121915B (fi) * 2004-02-06 2011-06-15 Neurofood Ab Oy Koostumus psoriasiksen hoitoon
EP1732538A1 (en) 2004-03-26 2006-12-20 Warner-Lambert Company LLC Use of a serine palmitoyltransferase (spt) inhibitor to treat atherosclerosis and dyslipidemia
WO2006042278A1 (en) 2004-10-12 2006-04-20 Forbes Medi-Tech (Research) Inc. Compounds and methods of treating insulin resistance and cardiomyopathy
US20070286909A1 (en) * 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
US20080058395A1 (en) 2006-06-30 2008-03-06 Sepracor Inc. Fused heterocyclic inhibitors of D-amino acid oxidase
WO2008118785A2 (en) 2007-03-23 2008-10-02 Tikvah Therapeutics Methods for treating depression using immediate-impact treatments and d-cycloserine
US20080241121A1 (en) 2007-04-02 2008-10-02 Daniela Salvemini Inhibitors of the ceramide metabolic pathway as adjuncts to opiates for pain
US8603753B2 (en) * 2008-07-09 2013-12-10 The Institute For Ethnomedicine Immunoassay for detection of neurotoxic amino acid associated with neurological disorders
WO2010132128A1 (en) * 2009-05-14 2010-11-18 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognitve functions in individuals with down syndrome and/or alzheimer's disease
WO2011104298A1 (en) * 2010-02-24 2011-09-01 Universität Zürich Prevention and treatment of diseases caused by elevated levels of deoxy-sphingolipids

Also Published As

Publication number Publication date
PT2782566T (pt) 2021-03-03
US20130156846A1 (en) 2013-06-20
CA2855854C (en) 2020-03-31
JP6265908B2 (ja) 2018-01-24
US20210153483A1 (en) 2021-05-27
US11974551B2 (en) 2024-05-07
IL232710A0 (en) 2014-07-31
CA2855854A1 (en) 2013-05-30
AU2012340563B2 (en) 2017-01-19
IL232710B (en) 2021-12-01
US11700840B2 (en) 2023-07-18
AU2012340563A1 (en) 2014-05-29
US11917986B2 (en) 2024-03-05
US20220000082A1 (en) 2022-01-06
JP2014534263A (ja) 2014-12-18
EP2782566B1 (en) 2021-01-06
EP2782566A4 (en) 2016-01-13
EP2782566A1 (en) 2014-10-01
US20140212893A1 (en) 2014-07-31
US20180027781A1 (en) 2018-02-01
ES2856063T3 (es) 2021-09-27
WO2013078395A1 (en) 2013-05-30

Similar Documents

Publication Publication Date Title
DK3520805T3 (da) Sammensætninger til behandling af myelofibrose
DK2919796T3 (da) Brug af akkermansia til behandling af stofskiftesygdomme
DK3321276T3 (da) Fusionsproteiner til behandling af metaboliske lidelser
DK2782566T3 (da) L-serin til anvendelse ved behandling af neurodegenerative lidelser
DK3305317T3 (da) Forbindelser til behandling af neuropsykiatriske forstyrrelser
DK2938740T3 (da) Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser
DK3811943T3 (da) Forbindelse til anvendelse til behandling af øjenlidelser
DK2900061T3 (da) Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling
DK2895156T3 (da) Fremgangsmåde til fremstilling af terapeutiske nanopartikler
DK2830662T3 (da) Fremgangsmåder til behandlng af hårtabsforstyrrelser
DK3054976T3 (da) Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose
DK2747763T3 (da) (bacterio-)chlorofyllfotosensibilisatorer til behandling af øjensygdomme og -lidelser
DK2838539T3 (da) Østrogenderivater til anvendelse i behandlingen af neurologiske forstyrrelser
DK3581199T3 (da) Fremgangsmåder til behandling eller reduktion af ødematøs fibrosklerotisk pannikulitis
DK2522342T3 (da) Topisk formulering til behandling af hyperkeratonisk hud
DK2838907T3 (da) Aminosteroider til behandlingen af en ptp1b-associeret sygdom
DK2822558T3 (da) Procaspase 3 aktivering ved hjælp af kombinations terapi
DK2705886T3 (da) Filtermekanisme
DK2906219T3 (da) Orvepitant til behandling af kronisk pruritus
BR112014004416A2 (pt) composições e métodos para o tratamento de doenças neurodegenerativas
DK2830645T3 (da) Neuregulin til anvendelse i behandling af perifær nervelæsion
DK2961426T3 (da) Behandling af sygdomme i centralnervesystemet ved intranasal indgivelse af immunoglobulin g
DK2807170T3 (da) Phragmalin-limonoider til behandlingen af seksuel dysfunktion
DK2892556T3 (da) Sammensætninger og fremgangsmåder til behandling af sygdomme
DK2701707T3 (da) Fremgangsmåde til behandling af dyskinesi